KPV tripeptide (Ac-Lys-Pro-Val-NH2) is a synthetic C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) evaluated in preclinical studies for its anti-inflammatory properties. Researched extensively for modulating inflammatory pathways within intestinal barrier models, KPV demonstrates intracellular signaling control without triggering melanogenic activity.
KPV tripeptide (Ac-Lys-Pro-Val-NH2) is a synthetic C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) evaluated in preclinical studies for its anti-inflammatory properties. Researched extensively for modulating inflammatory pathways within intestinal barrier models, KPV demonstrates intracellular signaling control without triggering melanogenic activity.
The KPV tripeptide represents the terminal amino acid sequence—Lysine-Proline-Valine—of the endogenous peptide hormone alpha-melanocyte-stimulating hormone (α-MSH). In molecular biology and biochemical research, this tripeptide is frequently synthesized with terminal modifications to yield Ac-KPV-NH2. N-terminal acetylation and C-terminal amidation enhance enzymic resistance against aminopeptidases and carboxypeptidases, thereby stabilizing the molecule during in vitro cell culture assays and ex vivo tissue studies.
Unlike its parent molecule α-MSH, which binds broadly across melanocortin receptors (MC1R through MC5R), the isolated kpv tripeptide exhibits a distinct mechanism of action. Preclinical literature indicates that KPV bypasses typical classic surface melanocortin receptor activation to enter target cells via specific peptide transporters, such as PepT1 (SLC15A1). This unique entry route allows researchers to investigate anti-inflammatory pathways independently of pigmentary or systemic endocrine pathways triggered by intact α-MSH.
Researchers analyzing high-purity research peptides often select KPV for its minimalistic sequence and stability profile. Due to its short chain length (three amino acids, MW ~383.5 g/mol in its un-capped form; ~425.5 g/mol as Ac-KPV-NH2), KPV serves as a prime candidate for investigating structural biology, peptide-membrane interactions, and targeted delivery mechanisms in mucosal biology.
The principal target in kpv peptide research is the nuclear factor kappa B (NF-κB) transcription factor cascade. NF-κB acts as a master regulator of inflammatory responses, directing the transcription of pro-inflammatory cytokines, chemokines, and adhesion molecules. In cell-based models stimulated with lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-α), KPV administration correlates with a marked reduction in NF-κB nuclear translocation.
In vitro data suggest that upon entry into the cytoplasm—facilitated by the PepT1 transporter—KPV interacts with intracellular target proteins to inhibit the phosphorylation and subsequent degradation of IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha). By preventing IκBα degradation, KPV retains the NF-κB p65/p50 heterodimer in its inactive cytoplasmic complex, thereby suppressing downstream pro-inflammatory gene expression.
This intracellular modulation results in diminished transcript and protein levels of key inflammatory mediators, including IL-1β, IL-6, IL-8, and TNF-α. Additionally, preclinical models demonstrate that KPV can decrease inducible nitric oxide synthase (iNOS) expression, curbing excessive nitric oxide production under acute inflammatory stress.
A primary focus of ac kpv nh2 investigation revolves around gastrointestinal epithelial health and mucosal barrier integrity. In rodent models of dextran sulfate sodium (DSS)-induced and dinitrobenzene sulfonic acid (DNBS)-induced colitis, researchers utilize KPV to evaluate its protective and restorative effects on the colonic epithelium. DSS exposure typically compromises tight junction proteins, leading to mucosal erosion, neutrophil infiltration, and systemic endotoxin translocation.
Studies evaluating orally or parenterally administered Ac-KPV-NH2 in DSS-treated mice report significant attenuation of disease activity index (DAI) scores. HistOLOGICAL analyses reveal preserved mucosal architecture, reduced crypt damage, and lower myeloperoxidase (MPO) activity—a hallmark marker of neutrophil accumulation. Furthermore, real-time quantitative PCR assays demonstrate that KPV supports expression levels of tight junction proteins, including zonula occludens-1 (ZO-1), occludin, and specific claudin isoforms.
For investigators exploring intestinal pathophysiology, access to fully characterized compounds is paramount. Analytical details regarding molecular weight and sequence purity for this compound can be reviewed on the official KPV tripeptide product page.
When designing preclinical experiments focused on mucosal healing and inflammatory signaling, researchers frequently compare KPV against other established peptide candidates. While KPV operates primarily via PepT1-mediated intracellular NF-κB inhibition, compounds like BPC-157 research peptide act through growth factor axis upregulation (such as VEGFR2) and nitric oxide pathway modulation. Conversely, tight junction modulators like Larazotide acetate research peptide function directly at the extracellular apical junctional complex to prevent zonulin-mediated disassembly.
In contrast to broader antimicrobial and immunomodulatory agents such as LL-37 research peptide, KPV exhibits minimal direct cytotoxic or lytic activity against bacterial membranes, relying instead on targeted intracellular host signaling modulation. Understanding these distinct mechanistic pathways enables researchers to design synergistic, dual-agent in vitro protocols aimed at assessing multi-target mucosal defense.
The capped analog Ac-KPV-NH2 represents the standard configuration utilized in rigorous quantitative biochemical assays. Unmodified tripeptides containing free N-terminal amino groups and C-terminal carboxyl groups are highly susceptible to rapid cleavage by serum peptidases, severely reducing their half-life in extracellular media.
N-terminal acetylation (Ac-) masks the positive charge at the amino terminus, mimicking a native peptide bond and hindering aminopeptidase recognition. Similarly, C-terminal amidation (-NH2) neutralizes the negative charge of the terminal carboxylate, conferring stability against carboxypeptidase degradation. Chemical characterization of Ac-KPV-NH2 yields the following parameters:
• Chemical Formula: C20H35N5O5 (for acetylated/amidated variant) • Molecular Mass: 425.52 g/mol • CAS Number: 67727-97-3 (base sequence: 67727-97-3) • Solubility: Highly soluble in sterile aqueous buffers (pH 6.0–7.4), dimethyl sulfoxide (DMSO), and isotonic saline solution. Researchers seeking additional technical documentation on chemical modification strategies can consult the comprehensive PX1 Research library.
To ensure reproducible quantitative data in cell culture and animal models, researchers must source reagents that meet stringent analytical benchmarks. Impurities such as truncated peptide sequences, residual coupling reagents (e.g., HBTU, piperidine), or heavy metals can introduce confounding variables into delicate cell-based assays.
PX1 Research enforces strict quality assurance criteria across every production batch of research peptides. Evaluating prospective suppliers requires verifying the following analytical standards:
1. High-Performance Liquid Chromatography (RP-HPLC): Ensures chemical purity of ≥98.0%, verifying the absence of incomplete peptide deletion sequences. 2. Mass Spectrometry (ESI-MS / MALDI-TOF): Confirms precise molecular mass identity matching the theoretical value of Ac-KPV-NH2. 3. Endotoxin Level Verification: Quantitative Chromogenic LAL testing to ensure bacterial endotoxin levels remain strictly <0.01 EU/mg, preventing premature immune cell activation in culture. 4. Lot-Specific Certificate of Analysis (COA): Detailed COAs provided with every lot, traceable to ISO 17025 accredited testing facilities. 5. Domestic Synthesis & Logistics: Manufactured within US-based GMP-compliant facilities and dispatched via same-day shipping (Monday–Friday) from CA and AZ fulfillment hubs.
Proper handling and storage protocols are vital to maintain the physical integrity and bioactivity of lyophilized kpv tripeptide. Upon receipt, unopened vials containing lyophilized powder should be stored at -20°C for short-term projects or -80°C for long-term preservation to minimize moisture accumulation and peptide degradation.
Reconstitution should be conducted under sterile laminar flow hoods using sterile bacteriostatic water, sterile phosphate-buffered saline (PBS, pH 7.4), or endotoxin-free water. For high-concentration stock solutions, allow the vial to equilibrate to room temperature before adding the reconstitution medium to prevent condensation inside the container.
Gently swirl or invert the vial until complete dissolution is achieved; aggressive vortexing or sonic agitation should be avoided to prevent mechanical shearing or aggregation. Reconstituted stock solutions should be aliquoted into single-use polypropylene microtubes to eliminate repeated freeze-thaw cycles. Aliquots stored at -20°C remain stable for several months, while working solutions kept at 4°C should be utilized within 7 to 14 days.
In vitro models utilizing epithelial monolayers (such as Caco-2, HT-29, or T84 cell lines) frequently deploy KPV to measure epithelial resistance. Using Transwell chamber systems, researchers measure Transepithelial Electrical Resistance (TEER) across cell monolayers exposed to inflammatory stressors like INF-γ or LPS.
Preclinical data indicate that pre-incubation or co-incubation with KPV attenuates the TEER drop typically induced by pro-inflammatory cytokines. This preservation of electrical resistance correlates with reduced paracellular flux of fluorescent tracer molecules, such as FITC-dextran (4 kDa), confirming enhanced tight junction stability.
In macrophage and dendritic cell cultures (e.g., RAW 264.7 lines), kpv peptide research focuses on inflammatory mediator profiling. Western blotting of cytoplasmic versus nuclear protein fractions allows quantitative assessment of p65 translocation, while ELISA assays quantify secretome changes in response to varying concentrations of Ac-KPV-NH2.
Academic institutions, biotechnology firms, and contract research organizations (CROs) require absolute lot consistency when ordering biochemical reagents. Variations in peptide synthesis, TFA salt conversion, or counterion presence (acetate vs. trifluoroacetate) can alter cellular responses and introduce experimental variance.
PX1 Research provides fully validated reagents suitable for high-throughput screening, cell culture experiments, and animal disease models. Principal investigators and laboratory procurement officers interested in bulk scaling, custom packaging, or establishing institutional supply lines can review options through our dedicated wholesale portal.
What is the molecular structure of the kpv tripeptide?
The kpv tripeptide is a three-amino-acid sequence consisting of L-Lysine, L-Proline, and L-Valine (Lys-Pro-Val). It represents the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). In research formulations, it is frequently synthesized as Ac-Lys-Pro-Val-NH2 (Ac-KPV-NH2) with N-terminal acetylation and C-terminal amidation to enhance enzymatic stability.
How does ac kpv nh2 differ from un-capped KPV tripeptide sequences?
Ac-KPV-NH2 features chemical capping modifications: an acetyl group on the N-terminus and an amide group on the C-terminus. These modifications protect the peptide from degradation by exopeptidases (aminopeptidases and carboxypeptidases) in biological fluids and cell culture media, prolonging its half-life during preclinical research compared to un-capped KPV.
What primary pathways are targeted in kpv peptide research?
KPV peptide research primarily targets the nuclear factor kappa B (NF-κB) signaling pathway. Preclinical studies indicate that KPV enters cells via the PepT1 transporter and inhibits the activation and nuclear translocation of NF-κB, leading to reduced transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
How is KPV tripeptide reconstituted for in vitro experimental protocols?
Lyophilized KPV tripeptide should be reconstituted in sterile, endotoxin-free water or phosphate-buffered saline (PBS, pH 7.4). The vial should equilibrate to room temperature before adding the solvent. Swirl gently to dissolve; avoid violent vortexing. Stock solutions should be aliquoted into single-use tubes and stored at -20°C or -80°C to prevent freeze-thaw degradation.
What role does KPV play in preclinical colitis and intestinal barrier research?
In preclinical colitis models (such as DSS-induced or DNBS-induced rodent models), KPV is researched for its ability to preserve mucosal architecture, decrease myeloperoxidase (MPO) activity, reduce neutrophil infiltration, and maintain expression of tight junction proteins like ZO-1 and occludin.
Does kpv tripeptide activate melanocortin receptors like alpha-MSH?
In vitro binding assays demonstrate that isolated KPV tripeptide does not significantly activate classic surface melanocortin receptors (such as MC1R or MC4R) in the manner that full-length α-MSH does. Instead, its cellular uptake and signaling modulation occur predominantly via PepT1 transporter-mediated intracellular pathways.
How should KPV tripeptide be stored to preserve long-term stability?
Lyophilized KPV tripeptide powder should be stored desiccated at -20°C or -80°C, where it remains stable for up to 24 months. Reconstituted aqueous liquid aliquots should be stored at -20°C or lower and used within 3 to 6 months. Avoid repeated freeze-thaw cycles.
Why is endotoxin testing critical when procuring Ac-KPV-NH2 for cell culture assays?
Endotoxins (lipopolysaccharides) are potent inflammatory stimulators. If a research peptide contains endotoxin contaminants, it can induce false positive inflammatory responses in cell cultures (e.g., macrophage activation), invalidating experimental results regarding anti-inflammatory efficacy. PX1 Research tests every lot to ensure endotoxin levels are <0.01 EU/mg.
Can KPV tripeptide be combined with other barrier-modulating peptides in research models?
Yes, researchers frequently design multi-agent in vitro protocols combining KPV with other gastrointestinal or mucosal research compounds, such as BPC-157 or Larazotide acetate, to investigate complementary signaling pathways involved in tight junction regulation and mucosal repair.
What documentation is provided with PX1 Research KPV tripeptide lots?
Every lot of KPV tripeptide from PX1 Research includes a comprehensive Certificate of Analysis (COA) detailing identity confirmation via Mass Spectrometry (MS), purity verification (≥98%) via High-Performance Liquid Chromatography (HPLC), and quantitative endotoxin test results from an independent ISO 17025 accredited laboratory.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.